Abstract
Curcumin (1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione) is commonly used as a spice, food additive or dietary pigment. Accumulating evidence suggests that curcumin has several pharmacologic effects, including anti-inflammatory, anti-oxidant and anti-cancer activities. The molecular mechanisms underlying the targets of curcumin are diverse and involve combinations of multiple signaling pathways, including NF-κB and STAT3 signaling. Thus, curcumin is one of the most promising phytochemicals that target various cancers and inflammation-mediated diseases. Clinical trials have been ongoing or completed for various cancers, including breast, pancreatic and colorectal cancers, and multiple myeloma. In this review, the molecular mechanisms and the issue of bioavailability are mainly discussed.
Keywords: Bioavailability, cancer, curcumin, inflammation, NF-κB, rupture.
Endocrine, Metabolic & Immune Disorders - Drug Targets
Title:Curcumin Targets in Inflammation and Cancer
Volume: 15 Issue: 2
Author(s): Atsuko Deguchi
Affiliation:
Keywords: Bioavailability, cancer, curcumin, inflammation, NF-κB, rupture.
Abstract: Curcumin (1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione) is commonly used as a spice, food additive or dietary pigment. Accumulating evidence suggests that curcumin has several pharmacologic effects, including anti-inflammatory, anti-oxidant and anti-cancer activities. The molecular mechanisms underlying the targets of curcumin are diverse and involve combinations of multiple signaling pathways, including NF-κB and STAT3 signaling. Thus, curcumin is one of the most promising phytochemicals that target various cancers and inflammation-mediated diseases. Clinical trials have been ongoing or completed for various cancers, including breast, pancreatic and colorectal cancers, and multiple myeloma. In this review, the molecular mechanisms and the issue of bioavailability are mainly discussed.
Export Options
About this article
Cite this article as:
Deguchi Atsuko, Curcumin Targets in Inflammation and Cancer, Endocrine, Metabolic & Immune Disorders - Drug Targets 2015; 15 (2) . https://dx.doi.org/10.2174/1871530315666150316120458
DOI https://dx.doi.org/10.2174/1871530315666150316120458 |
Print ISSN 1871-5303 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3873 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Quercetin and MicroRNA Interplay in Apoptosis Regulation in Ovarian Cancer
Current Pharmaceutical Design Pharmacogenomics of Cytochrome P450 Enzymes in Tumours
Current Pharmacogenomics Therapeutic Approach of Primary Bone Tumours by Bisphosphonates
Current Pharmaceutical Design Oxaliplatin-mediated Inhibition of Survivin Increases Sensitivity of Head and Neck Squamous Cell Carcinoma Cell Lines to Paclitaxel
Current Cancer Drug Targets Targeting Protein Kinase Inhibitors with Traditional Chinese Medicine
Current Drug Targets Resveratrol as an Enhancer of Apoptosis in Cancer: A Mechanistic Review
Anti-Cancer Agents in Medicinal Chemistry Role of Natural Phenolic Compounds in Cancer Chemoprevention via Regulation of the Cell Cycle
Current Pharmaceutical Biotechnology An Update on Circumventing Multidrug Resistance in Cancer by Targeting P-Glycoprotein
Current Cancer Drug Targets Synthetic Src-Kinase Domain Inhibitors and Their Structural Requirements
Anti-Cancer Agents in Medicinal Chemistry Pathological and Therapeutic Aspects of Long Noncoding RNAs in Osteosarcoma
Anti-Cancer Agents in Medicinal Chemistry Cyclin-Dependent Kinase as a Novel Therapeutic Target: An Endless Story
Current Chemical Biology Physcion and Physcion 8-O-β-D-glucopyranoside: Natural Anthraquinones with Potential Anticancer Activities
Current Drug Targets Melatonin, Autophagy and Intestinal Bowel Disease
Current Pharmaceutical Design TRYCAT Pathways Link Peripheral Inflammation, Nicotine, Somatization and Depression in the Etiology and Course of Parkinson’s Disease
CNS & Neurological Disorders - Drug Targets SUMOylation Modulates CFTR Biogenesis: Is the Pathway Druggable?
Current Drug Targets Nuclear Magnetic Resonance Spectroscopy of Lipids in Cancer
Current Organic Chemistry Vitamin D and Vitamin D Analogs in Cancer Treatment
Current Drug Targets Gene Therapy in In Vivo Isolated Perfusion Models
Current Gene Therapy Recent Progress in the Development of Natural ent-Kaurane Diterpenoids with Anti-tumor Activity
Mini-Reviews in Medicinal Chemistry Long Non-Coding RNA: An Emerging Paradigm of Pancreatic Cancer
Current Molecular Medicine